Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.79 |
| ▸ | PGR | P06401 | 4/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16337814 | 1.00 | NR3C2 (0.79) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11882535 | 1.00 | NR3C2 (0.79) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11882532 | 1.00 | NR3C2 (0.79) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL14935895 | 1.00 | NR3C2 (0.79) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11581628 | 0.92 | HIF1A (0.68) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11581632 | 0.92 | HIF1A (0.68) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL3049344 | 0.90 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL321463 | 0.90 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL20553192 | 0.89 | NR3C2 (0.82) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11293782 | 0.89 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2019-01-29 | — | — | US | claimed |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN INC (US) | 2018-05-31 | — | — | US | claimed |
| US-9717743-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2017-08-01 | — | — | US | claimed |
| US-20150005519-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2015-01-01 | — | — | US | claimed |
| US-8865691-B2 | Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-10-21 | — | — | US | claimed |
| US-20130123226-A1 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | claimed |
| US-20220218599-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | ALLERGAN, INC. | 2022-07-14 | — | — | US | disclosed |
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180036233-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | ALLERGAN, INC. | 2018-02-08 | — | — | US | disclosed |
| US-8865691-B2 | Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130123226-A1 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005519-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, MC2R, NR3C1 | NR3C2 1/4885PGR 73/4885NR3C1 3/4885 |
| US-20180036233-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | LSS, SBDS, SPAST | NR3C2 2701/4885PGR 2363/4885NR3C1 2676/4885 |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, MC2R, NR3C1 | NR3C2 1/4885PGR 73/4885NR3C1 3/4885 |
| US-20130123226-A1 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, NR3C1, HSD11B2 | NR3C2 1/4885PGR 64/4885NR3C1 2/4885 |
| US-20220218599-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | LSS, SBDS, SPAST | NR3C2 2701/4885PGR 2363/4885NR3C1 2676/4885 |
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | NR3C2, MC2R, NR3C1 | NR3C2 1/4885PGR 65/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.